There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump
May 13
Hong Kong (HSI) Biotech Industry Analysis
UpdatedMay 18, 2024
DataAggregated Company Financials
Companies47
- 7D-2.2%
- 3M13.3%
- 1Y-30.0%
- YTDn/a
Over the last 7 days, the Biotech industry has risen 1.1%, driven by gains in Shanghai Junshi Biosciences and Shanghai Henlius Biotech of 6.2% and 7.3%, respectively. However, the industry is down 32% over the past year. As for the next few years, earnings are expected to grow by 35% per annum.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 18 May 2024 | HK$369.6b | HK$49.8b | -HK$19,389,301,884.42 | 12.1x | -19.1x | 7.4x |
| Mon, 15 Apr 2024 | HK$341.5b | HK$49.6b | -HK$19,924,923,894.70 | 11x | -17.1x | 6.9x |
| Wed, 13 Mar 2024 | HK$350.5b | HK$47.4b | -HK$20,450,625,656.33 | 16.7x | -17.1x | 7.4x |
| Fri, 09 Feb 2024 | HK$322.1b | HK$47.2b | -HK$20,393,366,609.52 | 15.6x | -15.8x | 6.8x |
| Sun, 07 Jan 2024 | HK$376.7b | HK$47.0b | -HK$20,300,331,811.00 | 16.9x | -18.6x | 8x |
| Tue, 05 Dec 2023 | HK$414.5b | HK$47.1b | -HK$20,318,447,108.00 | 18.6x | -20.4x | 8.8x |
| Thu, 02 Nov 2023 | HK$412.6b | HK$45.1b | -HK$18,886,517,646.00 | 12.7x | -21.8x | 9.2x |
| Sat, 30 Sep 2023 | HK$400.5b | HK$45.0b | -HK$19,143,037,636.00 | 13.9x | -20.9x | 8.9x |
| Mon, 28 Aug 2023 | HK$373.5b | HK$39.2b | -HK$20,093,496,287.00 | 15.7x | -18.6x | 9.5x |
| Wed, 26 Jul 2023 | HK$405.9b | HK$35.6b | -HK$23,449,443,652.00 | 26.1x | -17.3x | 11.4x |
| Fri, 23 Jun 2023 | HK$396.9b | HK$35.6b | -HK$23,400,590,440.00 | 24.5x | -17x | 11.2x |
| Sun, 21 May 2023 | HK$427.6b | HK$36.2b | -HK$23,886,097,959.00 | 31x | -17.9x | 11.8x |
| Tue, 18 Apr 2023 | HK$461.6b | HK$37.0b | -HK$24,208,903,199.00 | 18.7x | -19.1x | 12.5x |
| Thu, 16 Mar 2023 | HK$405.7b | HK$33.2b | -HK$36,454,813,183.00 | 22.4x | -11.1x | 12.2x |
| Sat, 11 Feb 2023 | HK$442.0b | HK$34.8b | -HK$35,211,672,338.00 | 29.1x | -12.6x | 12.7x |
| Mon, 09 Jan 2023 | HK$426.7b | HK$34.6b | -HK$34,879,667,099.00 | 30.9x | -12.2x | 12.3x |
| Wed, 07 Dec 2022 | HK$358.8b | HK$33.6b | -HK$33,859,915,335.00 | 23.8x | -10.6x | 10.7x |
| Fri, 04 Nov 2022 | HK$347.8b | HK$33.4b | -HK$32,116,950,613.00 | 18.6x | -10.8x | 10.4x |
| Sun, 02 Oct 2022 | HK$286.1b | HK$34.0b | -HK$32,506,419,134.00 | 17.1x | -8.8x | 8.4x |
| Tue, 30 Aug 2022 | HK$327.7b | HK$33.8b | -HK$37,915,161,213.00 | 15.7x | -8.6x | 9.7x |
| Thu, 28 Jul 2022 | HK$336.0b | HK$32.8b | -HK$46,232,023,694.00 | 13.5x | -7.3x | 10.2x |
| Sat, 25 Jun 2022 | HK$383.3b | HK$33.1b | -HK$46,663,236,636.00 | 14.7x | -8.2x | 11.6x |
| Mon, 23 May 2022 | HK$352.6b | HK$34.1b | -HK$45,992,673,559.00 | 14.1x | -7.7x | 10.3x |
| Wed, 20 Apr 2022 | HK$345.7b | HK$36.4b | -HK$46,261,778,213.00 | 13.1x | -7.5x | 9.5x |
| Fri, 18 Mar 2022 | HK$313.2b | HK$34.8b | -HK$31,145,232,834.00 | 13.3x | -10.1x | 9x |
| Sun, 13 Feb 2022 | HK$293.8b | HK$31.1b | -HK$31,888,382,762.00 | 12.6x | -9.2x | 9.4x |
| Tue, 11 Jan 2022 | HK$365.6b | HK$31.1b | -HK$31,786,654,559.00 | 13.1x | -11.5x | 11.8x |
| Thu, 09 Dec 2021 | HK$467.0b | HK$31.1b | -HK$31,824,776,628.00 | 13.5x | -14.7x | 15x |
| Sat, 06 Nov 2021 | HK$449.2b | HK$30.9b | -HK$31,625,170,793.00 | 13.9x | -14.2x | 14.5x |
| Mon, 04 Oct 2021 | HK$513.8b | HK$30.5b | -HK$31,542,189,750.00 | 15.5x | -16.3x | 16.8x |
| Wed, 01 Sep 2021 | HK$514.6b | HK$30.2b | -HK$32,058,827,347.35 | 17.6x | -16.1x | 17x |
| Thu, 08 Jul 2021 | HK$651.9b | HK$30.2b | -HK$32,058,827,347.35 | 19.7x | -20.3x | 21.6x |
Price to Earnings Ratio
-23.6x
Current Industry PE
- Investors are pessimistic on the Hong Kong Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 11.5x is higher than the industry's current PS ratio of 7.5x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 22% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Hong Kong Biotech compare with similar industries?
| HK Market | 2.56% | |
| Healthcare | -0.91% | |
| Biotech | -2.19% | |
| Biotech | -2.19% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1877 Shanghai Junshi Biosciences | HK$13.54 | 7.3% +HK$906.1m | -50.4% | PS7.6x | |
| 2696 Shanghai Henlius Biotech | HK$17.98 | 4.5% +HK$423.9m | 43.4% | PE16.6x | |
| 2105 Laekna | HK$7.36 | 11.7% +HK$300.4m | n/a | PS5658.3x | |
| 2509 Qyuns Therapeutics | HK$28.45 | 5.0% +HK$299.8m | n/a | PS396.7x | |
| 2616 CStone Pharmaceuticals | HK$1.31 | 21.3% +HK$293.3m | -55.6% | PS3.3x |